Open AccessTuberculous drug-induced liver injury and treatment re-challenge in Human Immunodeficiency Virus co-infection
Author(s) -
Cecilia T. Costiniuk,
Bernadett I. Gosnell,
Thandekile C. Manzini,
Camille N Du Plessis,
M Y H Moosa
Publication year - 2015
Publication title -
journal of global infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 25
eISSN - 0974-8245
pISSN - 0974-777X
DOI - 10.4103/0974-777x.170499
Subject(s) - medicine , discontinuation , tuberculosis , interquartile range , regimen , adverse effect , incidence (geometry) , retrospective cohort study , human immunodeficiency virus (hiv) , liver injury , pediatrics , immunology , pathology , physics , optics
Tuberculosis drug-induced liver injury (TB-DILI) is the most common adverse event necessitating therapy interruption. The optimal re-challenge strategy for antituberculous therapy (ATT) remains unclear, especially in human immunodeficiency virus (HIV) co-infected individuals in high-prevalence settings such as South Africa.